HABP/VABP and Gram-Negative Resistance: Pathways to Early Effective Therapy

Comprehensive slideset featuring data on key concepts in HABP/VABP and gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.
Lilian Abbo Headshot
Lilian Abbo, MD, FIDSA
Keith S. Kaye, MD, MPH
Jason Pogue Headshot
Jason M. Pogue, PharmD
Format: Microsoft PowerPoint (.ppt)
File Size: 526 KB
Released: February 18, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

Prof. Sharon R. Lewin: expert insights on remdesivir for nonhospitalized adult and pediatric patients with COVID-19, from Clinical Care Options (CCO)

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: June 7, 2022

Prof. Sharon R. Lewin discusses ivermectin and the evolution of monoclonal antibody treatments during omicron, from Clinical Care Options (CCO)

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: June 7, 2022

Dr Kristen Marks on COVID-19 second booster dose: indication, which vaccine, and timing, from Clinical Care Options (CCO)

Kristen Marks, MD Released: May 20, 2022

Expert commentary on new data in RSV epidemiology from ECCMID 2022, as reported by Clinical Care Options (CCO)

Ting Shi, PhD Released: May 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings